Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Shein Targets $26B-$27B Valuation for Hong Kong IPO 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push 
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Add as a preferred source on Google
The enormous rally in Kodak shares is expected to continue after its 318 percent increase on Wednesday on the strength of the Trump administration's announcement that will be transformed into a pharmaceutical producer and would receive a $765 million loan to launch Kodak Pharmaceuticals.
The news propelled the company's shares to a more than 200 percent jump in Tuesday trading that continued on Wednesday with the shares ending with a 318 percent increase.
The stocks climbed over 650 percent at its highest on Wednesday, prompting the New York Stock Exchange to halt trading 20 times.
Kodak, a pre-digital era giant producer of film and cameras, filed for bankruptcy in 2012 and pivoted to turn itself into a materials and chemical company.
It emerged as a restructured business in 2013.
Kodak Pharmaceuticals will produce generic active pharmaceutical ingredients to reduce America's dependency on foreign drug makers.
Kodak CEO Jim Continenza noted that since the company already manufactures essential materials for some pharmaceuticals, the new mission is only expanding that capacity.
He added that it would take around three to three and a half years to establish the new production capacity.
